# Janux Therapeutics

Type: Company (JANX)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/janux-therapeutics
Canonical HTML page: https://getfinancebrief.com/entity/janux-therapeutics

## Recent coverage (1 stories)

### Janux Stock Slips After 46% Revenue Miss, $0.10 EPS Shortfall
2026-08-09 00:34:57 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Janux Therapeutics shares fell to $15.85 after Q2 revenue of $10.27M missed Wall Street estimates by 46%. The $0.35 EPS loss underscores rising costs, leaving the $966M market cap vulnerable to pipeline execution risks.
Full story: https://getfinancebrief.com/story/janux-earnings-miss-finance

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.